AGEN AGENUS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1098972 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.4%
TTM net income YoY187.7%
TTM EPS YoY114.6%
Revenue 3-yr CAGR9.9%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin38.9%
Net margin23.0%
FCF margin-77.5%
EBITDA margin40.6%
Returns
ROE—
ROA12.9%
ROIC (approx.)—
Asset turnover0.56x
Leverage & solvency
Liabilities / assets145.7%
Debt / equity—
Current ratio0.73x
Interest coverage0.85x
Cash quality & payout
Operating cash flow / net income-3.37x
Accruals ratio56.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $114.20M | $103.46M | $156.31M | $98.02M | $295.67M |
| Cost of revenue | $1.02M | $486,000 | $3.11M | $10.57M | $3.47M |
| Gross profit | $113.17M | $102.98M | $153.20M | $87.46M | $292.19M |
| R&D expense | $79.34M | $155.53M | $234.57M | $186.69M | $178.61M |
| SG&A expense | $54.39M | $71.88M | $78.74M | $81.01M | $76.36M |
| Operating income | -$20.17M | -$120.47M | -$159.55M | -$179.43M | $25.75M |
| Interest expense | $55.62M | $120.42M | $103.86M | $64.12M | — |
| Pretax income | -$3.08M | -$232.27M | -$257.44M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | $115,000 | -$227.21M | -$245.76M | -$220.07M | -$23.93M |
| EBITDA | -$10.17M | -$107.13M | -$145.96M | -$172.48M | $32.53M |
| EPS (basic) | 0.00 | -10.59 | -13.75 | -15.64 | -0.11 |
| EPS (diluted) | 0.00 | -10.59 | -13.75 | -15.64 | -0.11 |
| Weighted avg. shares (diluted) | 29.73M | 21.47M | 17.89M | 14.09M | 228,919 |
| Balance sheet | |||||
| Cash & equivalents | $3.00M | $40.44M | $76.11M | $178.67M | $291.93M |
| Short-term investments | $0 | — | — | $14.68M | $14.99M |
| Receivables | $1.83M | $407,000 | $25.84M | $2.74M | $1.52M |
| Current assets | $133.44M | $45.57M | $112.42M | $213.12M | $331.97M |
| PP&E, net | $15.47M | $120.09M | $133.42M | $133.02M | $60.03M |
| Goodwill | $24.09M | $24.09M | $24.72M | $25.47M | $24.88M |
| Intangibles | $3.04M | $3.38M | $4.41M | $6.23M | $8.49M |
| Total assets | $226.80M | $226.27M | $313.91M | $413.56M | $465.96M |
| Current liabilities | $323.49M | $221.40M | $255.90M | $188.95M | $156.94M |
| Short-term debt | $44.66M | $2.70M | $146,000 | $575,000 | $728,000 |
| Long-term debt | $0 | $30.47M | $12.77M | $12.58M | $12.82M |
| Total debt | $44.66M | $33.17M | $12.91M | $13.16M | $13.55M |
| Total liabilities | $504.66M | $532.70M | $462.30M | $468.46M | $418.05M |
| Shareholders' equity | -$271.11M | -$326.38M | -$160.33M | -$61.28M | $34.44M |
| Net debt | $41.66M | -$7.27M | -$63.20M | -$165.51M | -$278.38M |
| Shares outstanding | 35.32M | 23.63M | 19.72M | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$77.19M | -$158.31M | -$224.20M | -$175.37M | $10.14M |
| Capital expenditure | $6,000 | $576,000 | $9.95M | $53.06M | $33.81M |
| Free cash flow | -$77.20M | -$158.89M | -$234.16M | -$228.44M | -$23.67M |
| Investing cash flow | $1.19M | $27,000 | $3.40M | -$33.61M | -$43.15M |
| Financing cash flow | $36.59M | $122.84M | $119.87M | $95.83M | $225.26M |
| Depreciation & amortization | $10.00M | $13.34M | $13.59M | $6.95M | $6.79M |
| Stock-based compensation | $13.77M | $17.39M | $22.87M | $18.34M | $19.58M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.